2 results
Approved WMORecruiting
Objective: To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, withrespect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator.
Approved WMORecruiting
Objective: The primary aim of the study is to demonstrate that cervical administered ITB is a safe treatment of spasticity of the UE without deterioration of pulmonary function, respiration and sleep-related breathing disorders.